NBIX Vykat XR Safety: 7 Deaths, 100+ Serious Events

Neurocrine Biosciences (NBIX) is defending its newest $1 billion-plus hopeful after post-marketing surveillance flagged serious safety concerns for Vykat XR, the first FDA-approved drug for hyperphagia, the insatiable hunger that marks Prader-Willi syndrome (PWS). A STAT investigation reported seven deaths and more than 100 serious adverse event reports, mostly hospitalizations for edema, respiratory, and cardiac complications, in the FDA’s Adverse Event Monitoring System (AEMS) as of July 31.

The signal is real but its meaning is contested. AEMS, also known as FAERS, is a voluntary reporting system: it captures possible drug side effects but does not prove causation. Prader-Willi syndrome, which affects roughly one in 15,000 people, is a genetic disorder in which a missing chromosome region disrupts satiety signaling, leaving patients with a drive to eat that is nearly impossible to control. The clinicians and patient groups who flagged the reports, including the Foundation for Prader-Willi Research and the International Prader-Willi Syndrome Organisation, acknowledge that the affected patients had complex medical histories, multiple medications, and often pre-existing obesity. People with PWS already carry elevated baseline risk of respiratory and cardiac problems.

Neurocrine is standing by the drug. The company said Vykat XR “has a compelling risk-benefit profile in the context of a very serious disease” and noted it reviewed adverse event data during its acquisition of Soleno Therapeutics, which closed May 18, 2026, for $2.9 billion. BMO analysts wrote that the events “do not appear to have been revealed in clinical testing,” which could make physicians more cautious about prescribing.

The stakes are material. Vykat XR, a diazoxide choline extended-release pill, generated $54 million in a partial second quarter, and the company has pointed to a $350 million to $400 million annual run rate. NBIX shares closed at $152.57, down from roughly $180 in late July. The franchise is meant to offset looming generic competition for Ingrezza, Neurocrine’s top product.

The safety news lands in a hard disease space. Aardvark Therapeutics terminated its Phase 3 HERO trial of ARD-101 in PWS earlier this year after cardiac concerns, underscoring how difficult it is to treat this population safely. Vykat XR remains the only approved option, which cuts both ways: patients have no alternative, but any label change or prescribing slowdown would hit the product directly.

What to watch next: whether the FDA issues a safety communication or label update, and whether new prescriptions slow when Neurocrine reports third-quarter results. For the financial picture behind the Vykat franchise, see the NBIX Q2 earnings coverage.

Source: STAT News investigation